"Drugs that make it into Phase II clinical trials have a success rate of about 50 %," says Chang. "Americans see these drugs as having investment value, as being worth a roll of the dice. Look at American biotech company IPOs. Most don't even have products on the market yet!"
「一個已進入第二期臨床試驗的新藥，它的成功率約有 50 %，對美國投資人來說，這就是投資價值，值得一搏，」張念原分析：「美國的生技公司初上市時，它們的產品幾乎都還沒問世！」